{"podcast":{"title":"Business Of Biotech","slug":"business-of-biotech-123501","podcast_index_feed_id":123501,"rss_url":"https://rss.buzzsprout.com/1011661.rss","website_url":"https://www.bioprocessonline.com/solution/the-business-of-biotech-podcast","image_url":"https://storage.buzzsprout.com/35u0bccu9j9xpr9zrrjias54otax?.jpg","author":"Ben Comer","episode_count":310,"summary":"The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.","last_synced_at":"2026-06-08T22:18:30.179389+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501"},"episode":{"title":"Radiotherapeutics For Neuroendocrine Tumors With Perspective Therapeutics' Thijs Spoor","slug":"radiotherapeutics-for-neuroendocrine-tumors-with-perspective-therapeutics-thijs-spoor","published_at":"2026-04-06T10:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/radiotherapeutics-for-neuroendocrine-tumors-with-perspective-therapeutics-thijs-spoor","show_page_url":"https://stenobird.com/podcast/business-of-biotech-123501","url":"https://www.buzzsprout.com/1011661/episodes/18946349-radiotherapeutics-for-neuroendocrine-tumors-with-perspective-therapeutics-thijs-spoor.mp3","audio_url":"https://www.buzzsprout.com/1011661/episodes/18946349-radiotherapeutics-for-neuroendocrine-tumors-with-perspective-therapeutics-thijs-spoor.mp3","summary":"We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Thijs Spoor, CEO at Perspective Therapeutics, a company developing Pb 212 (lead)-based therapeutics, talks about why radiopharmaceuticals are surging again and why biodistribution is the make-or-break variable when your payload is a radioactive isotope. Thijs discusses the reasons behind Perspective's investment in a proprietary generator for therapeutic production, manufacturing a...","meta_description":"We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Thijs Spoor, CEO at Perspective Therapeutics, a…","key_points":[],"chapters":[],"topics":[],"duration_seconds":2426,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/radiotherapeutics-for-neuroendocrine-tumors-with-perspective-therapeutics-thijs-spoor/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/radiotherapeutics-for-neuroendocrine-tumors-with-perspective-therapeutics-thijs-spoor.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}